Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 11/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 4/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2058438 | 1.00 | CA1 (0.46) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL18809767 | 0.87 | CA1 (0.45) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL384009 | 0.82 | CA1 (0.44) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL6685916 | 0.82 | CA1 (0.44) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL384991 | 0.82 | CA1 (0.44) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL6683824 | 0.81 | CA1 (0.42) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL19489244 | 0.79 | CA1 (0.50) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL2058674 | 0.79 | CTSK (0.53) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL963465 | 0.79 | CTSK (0.53) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL327825 | 0.79 | CTSK (0.53) | CA1CA2CA7CTSKCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3231798-B1 | THIAZOLE INTERMEDIATES USEFUL IN THE PREPARATION OF RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS INC (US) | 2019-10-09 | — | — | EP | disclosed |
| US-9920048-B2 | Substituted pyrimidines for inhibiting Raf kinase activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| EP-3231798-A1 | THIAZOLE INTERMEDIATES USEFUL IN THE PREPARATION OF RAF KINASE INHIBITORS | Sunesis Pharmaceuticals, Inc. (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-3231798-A1 | THIAZOLE INTERMEDIATES USEFUL IN THE PREPARATION OF RAF KINASE INHIBITORS | Sunesis Pharmaceuticals, Inc. (US) | 2017-10-18 | — | — | EP | disclosed |
| US-20170158686-A1 | Compounds Useful as Raf Kinase Inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170158686-A1 | Compounds Useful as Raf Kinase Inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| EP-2167489-B1 | PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS INC (US) | 2017-05-03 | — | — | EP | disclosed |
| EP-2167489-B1 | PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS INC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-20170042858-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY | 2017-02-16 | — | — | US | disclosed |
| US-9556177-B2 | Substituted 1,3-thiazoles as synthetic intermediates for preparation of Raf kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20090036419-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| US-20090036419-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| US-20090036419-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| WO-2009006404-A2 | HETEROCYCLIC COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009006389-A2 | PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| US-20090005359-A1 | Heterocyclic Compounds Useful as RAF Kinase Inhibitors | SUNESIS PHARMACEUTICALS, INC (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005359-A1 | Heterocyclic Compounds Useful as RAF Kinase Inhibitors | SUNESIS PHARMACEUTICALS, INC (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005359-A1 | Heterocyclic Compounds Useful as RAF Kinase Inhibitors | SUNESIS PHARMACEUTICALS, INC (US) | 2009-01-01 | — | — | US | disclosed |
| US-20080194672-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | TRANZYME PHARMA INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080194672-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | TRANZYME PHARMA INC. | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036419-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | CA1 4280/4885CA2 3466/4885CA7 3789/4885 |
| US-20170158686-A1 | Compounds Useful as Raf Kinase Inhibitors | BRAF, RAF1, ARAF | CA1 4280/4885CA2 3466/4885CA7 3789/4885 |
| US-20170042858-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | GHSR, GHRHR, GIPR | CA1 4766/4885CA2 4387/4885CA7 4709/4885 |
| US-20090005359-A1 | Heterocyclic Compounds Useful as RAF Kinase Inhibitors | BRAF, RAF1, ARAF | CA1 4330/4885CA2 3813/4885CA7 3828/4885 |
| US-20080194672-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | GHSR, GHRHR, GIPR | CA1 4837/4885CA2 4575/4885CA7 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.